

1 **Diagnostic accuracy of superb microvascular imaging (SMI) in**
2 **detecting intraplaque neovascularization (IPN): A systematic review**
3 **and meta-analyses protocol**

4 **Introduction**

5 The atherosclerotic disease (e.g., myocardial infarction and stroke) has become the
6 top killer worldwide [1, 2]. For instance, the atherosclerotic plaques can cause carotid
7 artery stenosis and “vulnerable plaques” can even lead to ischemic stroke due to the
8 rupture of the plaques and the formation of thrombi [3]. Therefore, to optimize the
9 management of atherosclerotic disease, evaluation of atherosclerotic plaque
10 vulnerability is vital.

11 The intraplaque neovascularization (IPN) has been proven as a risk factor to
12 evaluate atherosclerotic plaque vulnerability [4]. Ultrasound imaging techniques,
13 including contrast-enhanced carotid ultrasonography (CEUS) and superb
14 microvascular imaging (SMI), can effectively indicate IPN features in patients with
15 carotid stenosis. However, the SMI has the advantage of being less invasive compared
16 to the CEUS, because the SMI does not use contrast agents as CEUS but uses
17 adaptive principles to display low-velocity blood flow signals [5]. Recent published
18 meta-analysis has shown that SMI and CEUS display an excellent agreement in
19 detecting carotid IPN [6, 7]. However, the accuracy of SMI was inconsistent due to
20 the small sample sizes for each study [6, 7]. To our best knowledge, there was no
21 synthesized data on the accuracy of SMI in detection of the IPN in existing evidence.

22 The primary objective of this study was to assess the accuracy of SMI in the

23 detection of carotid IPN in patients with atherosclerotic plaque(s). Secondary
24 objectives included 1) to investigate the correlation between histopathological
25 intraplaque vessel density and SMI plaque neovascularization, and 2) to investigate
26 relationship between SMI results and clinical symptoms or events.

27 **Methods**

28 This systematic review and meta-analysis do not need the Research Ethics Board
29 approval because we will use the published evidence to do the data synthesis. The
30 reporting of the present project will follow the Preferred Reporting Items for
31 Systematic Review and Meta-Analyses of individual participant data: the
32 PRISMA-IPD Statement [8].

33 *Eligibility criteria*

34 The inclusion criteria for the included studies included 1) original studies (e.g.,
35 randomized controlled trials (RCT), cohort studies, cross-sectional studies, and
36 case-control studies), 2) patients with carotid plaque(s), 3) having information of the
37 diagnostic accuracy of SMI in the evaluation of IPN, and 4) having information of
38 pathologic evaluations or CEUS as the reference test. The exclusion criteria included:
39 1) duplicate publications, 2) study design as systematic review, meta-analysis,
40 editorial, protocol, letters, or case reports, 3) papers' full text not available, and 3)
41 studies without sufficient data to perform the accuracy assessment of the SMI.

42 *Literature search*

43 We searched databases of Cochrane Library, Embase, Medline, Wanfang database,
44 and China National Knowledge Infrastructure (CNKI) until January 17, 2023. The

45 detailed search strategies were described in **Appendix 1**. Language restriction was
46 applied as English. The key search terms included “carotid,” “plaque,” “fatty streak,”
47 “Fibroatheroma,” “neovascularization,” and “superb microvascular imaging.” The
48 bibliographies of the related papers (reviews, meta-analysis, and potential eligible
49 studies) will be checked to find other potential articles. Besides, we will check
50 published and conference proceedings for eligible data or references.

51 *Study selection*

52 Two independent reviewers will perform the title and abstract screening to generate
53 the potentially relevant study list according to the eligibility criteria. Then, the full
54 texts of the papers of the potential eligible study list will be extracted to do the
55 full-text review to further confirm the eligibility of the studies. The inconsistent
56 between the two reviewers will be resolved by discussion or refer to the third
57 authority. The workflow of the study selection can be found in **Figure 1**.

58 *Data collection*

59 Two study team members will independently perform the data extraction using a
60 pre-test data collection form. Discrepancies were resolved by discussion or by referral
61 to a third authority. The data collection will include information of authors,
62 publication year, study country, study design, patient demographics, SMI related data,
63 and index test information.

64 *Outcomes*

65 The primary outcome of the study was the accuracy of SMI in the detection of carotid
IPN in patients with atherosclerotic plaques, which was measured using sensitivity,

specificity, positive likelihood ratio (LR+), negative likelihood ratio (LR-), and diagnostic odds ratio (DOR) analyses. Sensitivity refers to the probability of the positive results of SMI given that the patients with IPN. The equation of the sensitivity = the positive (TP)/ (the false positive (FP) + TP). The specificity refers to the probability of the negative results of SMI given that the patients without IPN. The equation of the specificity = true negative (TN)/ (false negative (FN) + TN).

66 We prefer the reference test to pathologic evaluations first. However, if
67 pathologic evaluation results are not available, the CEUS results were performed as
68 the reference test. The target condition was carotid IPN. In different category of the
69 carotid IPN for SMI, CEUS, and pathologic evaluation results, we will count
70 moderate (linear IPN) and severe diagnosis (multiple linear IPNs) as a positive result,
71 and the no IPN or spot IPN as negative results due to the difference of their following
72 clinical treatments.

73 The secondary outcomes include the intraplaque vessel density, intraplaque
74 bleeding, and transient ischemic attack (TIA) or stroke.

75 ***Study risk of bias assessment***

76 Two study team members will independently perform the risk of bias the Quality
77 Assessment of Diagnostic Accuracy Studies (QUADAS-2) criteria [9]. There are four
78 key domains in the QUADAS-2 tool, including patients' selection, index test,
79 reference standards and follow and timing assess methodological quality. The quality
80 is graded as "no" for low quality, "yes" for high quality or "unclear" if the
81 information was not available.

82 ***Synthesis methods***

83

84 We will perform the statistical analysis of the SMI accuracy according to Cochrane
85 guidelines for diagnostic test accuracy (DTA) reviews [10]. We will apply forest plots
86 and in receiver-operating characteristic plots to visually explore the variation between
87 the included studies on the sensitivity and specificity of SMI their 95% confidence
88 intervals (CI) for detection IPN. We used the bivariate random effects model to
89 summarize sensitivity and specificity. All data analysis will be performed by using the
90 STATA software, version 16.0 (Stata Corp., College Station, TX, USA) [11]. We
91 calculated post-test probabilities of occurrence of the IPN following positive and
92 negative MIS outcomes for in the included studies. We applied Cochran's Q-statistic
93 and I^2 test to evaluate potential heterogeneity between studies. The random effects
94 model was applied if it indicated significant heterogeneity ($P < 0.1$ for Q test or I^2 test
95 exceeded 50%) or fixed effects model was used. Sensitivity analysis will be
96 performed to evaluate the influence of each individual study on the overall estimate.
97 Begg's funnel plot and Egger's test will be used to assess publication bias [9].

98 Subgroup analyses will be performed to explore variation in test performance
99 according to different reference indexes (CEUS and pathologic evaluation). The
100 meta-regression will be applied to investigate the potential heterogeneity by including
101 the variables of age, percentage of male, percentage of having hypertension,
102 percentage of having diabetes mellitus, percentage of having diabetes mellitus,
103 dyslipidemia, and machine type.

104 ***Certainty assessment***

105 We will apply the Grading of Recommendations, Assessment, Development, and

106 Evaluation (GRADE) rating system to assess certainty in the body of evidence for
107 accuracy [12]. Detailed GRADE guidance was applied to assess the risk of bias,
108 imprecision, inconsistency, indirectness, and publication bias. We will describe the
109 GRADE assessment results with a summary table.

110 **Discussion**

111 The results of the present study will be useful for the practice. We plan to share the
112 final results in national and international conferences and submitted it to a
113 peer-reviewed academic journal.

119

120 **References**

- 121 1. Fan J, Watanabe T: **Atherosclerosis: Known and unknown.** *Pathol Int* 2022, **72**(3):151-160.
- 122 2. Agarwal S, Sud K, Thakkar B, Menon V, Jaber WA, Kapadia SR: **Changing Trends of**
123 **Atherosclerotic Risk Factors Among Patients With Acute Myocardial Infarction and Acute**
124 **Ischemic Stroke.** *Am J Cardiol* 2017, **119**(10):1532-1541.
- 125 3. Baradaran H, Gupta A: **Brain imaging biomarkers of carotid artery disease.** *Ann Transl Med*
126 2020, **8**(19):1277.
- 127 4. Boswell-Patterson CA, Héту MF, Kearney A, Pang SC, Tse MY, Herr JE, Spence M, Zhou J, Johri
128 AM: **Vascularized Carotid Atherosclerotic Plaque Models for the Validation of Novel**
129 **Methods of Quantifying Intraplaque Neovascularization.** *J Am Soc Echocardiogr* 2021,
130 **34**(11):1184-1194.
- 131 5. Zamani M, Skagen K, Scott H, Lindberg B, Russell D, Skjelland M: **Carotid Plaque**
132 **Neovascularization Detected With Superb Microvascular Imaging Ultrasound Without Using**
133 **Contrast Media.** *Stroke* 2019, **50**(11):3121-3127.
- 134 6. Song Y, Xing H, Zhang Z, Felix LO: **Detection of Carotid Atherosclerotic Intraplaque**
135 **Neovascularization Using Superb Microvascular Imaging: A Meta-Analysis.** *Journal of*
136 *ultrasound in medicine : official journal of the American Institute of Ultrasound in Medicine*
137 2021, **40**(12):2629-2638.
- 138 7. Yang F, Wang C: **Consistency of superb microvascular imaging and contrast-enhanced**
139 **ultrasonography in detection of intraplaque neovascularization: A meta-analysis.** *PloS one*
140 2020, **15**(7):e0230937.
- 141 8. Stewart LA, Clarke M, Rovers M, Riley RD, Simmonds M, Stewart G, Tierney JF: **Preferred**
142 **Reporting Items for Systematic Review and Meta-Analyses of individual participant data:**
143 **the PRISMA-IPD Statement.** *Jama* 2015, **313**(16):1657-1665.

- 144 9. Whiting PF, Rutjes AW, Westwood ME, Mallett S, Deeks JJ, Reitsma JB, Leeflang MM, Sterne
145 JA, Bossuyt PM: **QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy**
146 **studies**. *Ann Intern Med* 2011, **155**(8):529-536.
- 147 10. Macaskill P, Gatsonis C, Deeks J, Harbord R, Takwoingi Y: **Cochrane handbook for systematic**
148 **reviews of diagnostic test accuracy**. In.: Version; 2010.
- 149 11. Reitsma JB, Glas AS, Rutjes AW, Scholten RJ, Bossuyt PM, Zwinderman AH: **Bivariate analysis**
150 **of sensitivity and specificity produces informative summary measures in diagnostic reviews**.
151 *J Clin Epidemiol* 2005, **58**(10):982-990.
- 152 12. Brozek JL, Akl EA, Jaeschke R, Lang DM, Bossuyt P, Glasziou P, Helfand M, Ueffing E,
153 Alonso-Coello P, Meerpohl J *et al*: **Grading quality of evidence and strength of**
154 **recommendations in clinical practice guidelines: Part 2 of 3. The GRADE approach to**
155 **grading quality of evidence about diagnostic tests and strategies**. *Allergy* 2009,
156 **64**(8):1109-1116.
- 157 13. Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, Shamseer L, Tetzlaff
158 JM, Akl EA, Brennan SE *et al*: **The PRISMA 2020 statement: an updated guideline for**
159 **reporting systematic reviews**. *Bmj* 2021, **372**:n71.

160

161 **Table 1.** The characteristics of XXXX of the 5 included studies.

First author (publication year), country	Study Design	Total sample size (experimental arm/control arm), n	Age (years), mean±SD or specified	Infertility duration (experimental arm/control arm)	Surgery procedures	The number of IVF cycles (experimental arm/control arm)	Primary outcome(s)
Bianchi et al. (2009), Brazil	Prospective cohort study	169 (64/105)	32.0±3.0	29.0±20.0 months /35.0±18.0 months	Extensive laparoscopic excision of DIE before IVF	86/153	The number of mature oocytes retrieved
Capelle et al. (2015), France	Retrospective cohort study	177 (112/65)	31.0 (mean)	3.2 years/3.4-3.5 years	Incomplete operations and complete surgical mass removal of DIE lesions.	Not specified	Pregnancy rates
Bendifallah et al. (2017), France	Retrospective cohort study	110 (55/55)	32.0 (mean)	3.0 years/3.0 years	Extensive laparoscopic excision of DIE before IVF	80/82	Live birth rates
Mounsambote et al. (2017), France	Retrospective cohort study	72 (35/37)	32.6±4.0	Not specified	Adhesion lysis, fallopian tube resection, uterosacral ligament lesion resection, ureter and intestinal surface lesion removal.	58/54	Pregnancy rates
Maignien et al. (2020), France	Retrospective cohort study	222 (155/67)	33.0±3.9	4.0±2.0 years /4.0±2.4 years	Ovarian cyst stripping and excision of DIE before IVF	311/129	The number of mature oocytes retrieved

162 Abbreviation: SD, standard deviation; DIE, deep infiltrative endometriosis; IVF, in vitro fertilization;

Figure Legends

Figure 1. PRISMA flow diagram for article selection for meta-analysis.

Figure 2. Forest plot of XXXX.

Figure 3. Forest plot of XXX.

Figure 4. Funnel plots of XXX.




Figure 1. PRISMA flow diagram for article selection for meta-analysis [13].

Appendix 1. Literature search strategies.

Cochrane Library CENTRAL search strategy

Search Name:

Date Run: 18/01/2023 00:49:26

Comment:

ID Search Hits

#1 (Superb microvascular imaging):ti,ab,kw 15

#2 (SMI):ti,ab,kw 924

#3 (neovascularization of carotid plaque):ti,ab,kw 5

#4 #1 Or #2 927

#5 #3 and #4 1

Database: OVID Medline Epub Ahead of Print, In-Process & Other Non-Indexed Citations, Ovid MEDLINE(R) Daily and Ovid MEDLINE(R) 1946 to present

Database: Ovid MEDLINE(R) ALL <1946 to January 13, 2023>

Search Strategy:

1 carotid.mp. (152391)

2 ("plaque*" or "fatty streak" or "fibroatheroma").mp. (164774)

3 ("vulnerability" or "stability" or "neovascularization").mp. (754458)

4 superb microvascular imaging.mp. (277)

5 1 and 2 and 3 and 4 (23)

Database: Embase <1974 to 2021 December 17>

Database: Embase Classic+Embase <1947 to 2023 January 13>

Search Strategy:

-
- 1 carotid.mp. (239439)
 - 2 ("plaque*" or "fatty streak" or "fibroatheroma").mp. (238344)
 - 3 ("vulnerability" or "stability" or "neovascularization").mp. (885705)
 - 4 superb microvascular imaging.mp. (393)
 - 5 1 and 2 and 3 and 4 (37)
